Correction: On Q22 of Saturday’s quiz, I selected the wrong “correct” answer. The risk of radiation-induced malignancy for children getting chest CT for trauma did not justify routine scanning given the low number of aortic injuries detected. Thanks to Dr. Strauss for pointing this out.
Written by Clay Smith
Neither droperidol 1.25mg IV nor ondansetron 8mg IV was better than placebo in achieving an 8mm reduction in nausea on visual analog scale (VAS). But ondansetron was slightly better than droperidol and placebo for overall mean nausea reduction and in patients experiencing the desired effect.
Antiemetics aren’t all that…
This was a RCT comparing droperidol 1.25mg IV, ondansetron 8mg IV, and placebo 0.9% saline IV. At 30 minutes, there was no difference in the primary outcome of nausea by at least 8mm, as measured on VAS. Nausea improved 8mm on VAS in 75%, 80%, and 76% of patients, respectively. Ondansetron was more effective than placebo and droperidol for a secondary outcome of mean VAS score improvement, -34mm vs 24mm vs 29mm, respectively. The study was stopped early after the interim analysis showed futility for showing superiority of the active drugs for the primary outcome, enrolling 215 out of a planned 378 patients. More patients in the placebo group requested additional antinausea medication, 30% placebo; 15% droperidol; 23% ondansetron. Droperidol was more sedating than the other two. All patients received 0.9% saline at 250mL/hr x 4 hours. IV fluid alone may have been effective at relieving nausea.
How will I apply this in practice? Ondansetron wasn’t worthless. Another secondary outcome, experiencing the desired effect, was much better for ondansetron than placebo, NNT = 7. So, we can tell patients that ondansetron, in addition to IV fluid, is likely to further decrease nausea.
The Short Coat posted a great, quick review of this article.
Randomized placebo-controlled trial of droperidol and ondansetron for adult emergency department patients with nausea. Acad Emerg Med. 2018 Oct 28. doi: 10.1111/acem.13650. [Epub ahead of print]
Open in Read by QxMD